Background Few options exist for patients with locally advanced or metastatic urothelial
carcinoma after progression with platinum-based chemotherapy. We aimed to assess the …

290 Background: Atezo (anti–PD-L1) has demonstrated safety and efficacy in a broad range
of cancers and is approved in the United States for mUC previously treated with platinum …

LBA441 Background: Two interim OS analyses from IMvigor130 demonstrated non-
statistically significant OS benefit with atezo monotherapy (Arm B) vs placebo+ platinum …

Abstract Background Atezo (anti–PD-L1) is approved for platinum-treated mUC and other
indications. Here, we evaluated long-term OS and safety data from IMvigor211, a …

BACKGROUND: Atezolizumab is an immune checkpoint inhibitor (ICI) and a frontline
treatment of patients with cisplatin-ineligible advanced urothelial carcinoma (UC). There is …

574 Background: Over the past years, the treatment landscape of platinum-refractory mUC
has drastically changed with the advent of immunotherapy. More recently, several new …

Background and importance Few options exist for patients with metastatic urothelial
carcinoma (MUC). Atezolizumab, an anti-PD-L1 immune checkpoint inhibitor, has been …

LBA440 Background: The IMvigor130 primary analysis demonstrated statistically significant
PFS benefit with 1L atezo+ plt/gem (Arm A) vs placebo+ plt/gem (Arm C) in pts with mUC …

Abstract Background The studies IMvigor 210 cohort 2 and IMvigor211 evaluated the
efficacy of atezolizumab in patients with locally advanced or metastatic urothelial cancer …

Introduction: Until recently, there has been little advancement in the management of invasive
and metastatic urothelial cancer in over 30 years, and outcomes with cisplatin-based …